Department of Gynecology, Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, China.
Department of Gynecology and Obstetrics, Hebei General Hospital, Shijiazhuang, 050000, China.
J Ovarian Res. 2019 Mar 27;12(1):29. doi: 10.1186/s13048-019-0499-z.
To identify the plasma protein biomarkers related to the chemoresistance of postoperative recurrence of epithelial ovarian cancers.
Forty plasma samples from patients in chemotherapy-sensitive and chemotherapy-resistant groups (20 for each group) were collected at Gynecology Department in the Fourth Hospital of Hebei Medical University from September 2013 to September 2014. The differentially expressed proteins between two groups were screened with two-dimensional gel electrophoresis (2-DE) and further analyzed by matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF-MS).
Thirty-four differentially expressed spots were identified between the two groups. Compared with the chemo-sensitive group, 21 protein spots were up-regulated and 13 were down-regulated in the chemoresistant group, in which 14 differentially expressed proteins were identified by the Mass spectrometry and Mascot search. Among the 14 proteins, complement C4-A, IgJ chain, clusterin, α-1-antitrypsin and carbonic anhydrase 1 were up-regulated, and transthyretin, haptoglobin, β-2-glycoprotein, Ig γ-2 chain C region, Ig γ-1 chain C region, complement factor I light chain, Igκ chain C region, complement C3 and apolipoprotein E were down-regulated in the chemoresistant group when compared with the chemosensitive group.
The up-regulated proteins including transthyretin, apolipoprotein E and haptoglobin proteins and the down-regulated proteins such as clusterin, carbonic anhydrase 1, alpha-1-antitrypsin were differentially expressed in the plasma between the chemo-sensitive group and the chemoresistant group, which may be potential biomarkers for predicting the chemotresistance of epithelial ovarian cancer patients.
鉴定与上皮性卵巢癌术后复发化疗耐药相关的血浆蛋白生物标志物。
2013 年 9 月至 2014 年 9 月,河北医科大学第四医院妇科收集化疗敏感组和化疗耐药组(每组 20 例)的 40 例血浆样本。采用二维凝胶电泳(2-DE)筛选两组间差异表达蛋白,基质辅助激光解吸电离飞行时间质谱(MALDI-TOF-MS)进一步分析。
两组间共鉴定出 34 个差异表达斑点。与化疗敏感组相比,耐药组有 21 个蛋白点上调,13 个蛋白点下调,经质谱和 Mascot 搜索鉴定出 14 个差异表达蛋白。在这 14 个蛋白中,补体 C4-A、IgJ 链、载脂蛋白、α-1-抗胰蛋白酶和碳酸酐酶 1 上调,转甲状腺素、触珠蛋白、β-2-糖蛋白、Igγ-2 链 C 区、Igγ-1 链 C 区、补体因子 I 轻链、Igκ 链 C 区、补体 C3 和载脂蛋白 E 下调。
与化疗敏感组相比,耐药组患者血浆中转甲状腺素、载脂蛋白 E 和触珠蛋白等上调蛋白和载脂蛋白、碳酸酐酶 1、α-1-抗胰蛋白酶等下调蛋白差异表达,可能是预测上皮性卵巢癌患者化疗耐药的潜在生物标志物。